AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Learn how a yield-focused dividend ETF can fit into a retirement plan, delivering income while maintaining simplicity and liquidity.
19,425 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
As KBR prepares to unveil its Q4 2025 results, investors should focus on backlog, margins, and free cash flow. This g...
Garmin, Synaptics, and QuantumScape blend device hardware, AI-ready tech, and next-gen batteries in a low-profile tri...
State Farm is rolling out an AI-driven claims platform as part of a broader push to reinvent pricing and service. The...
Micron Technology rides the AI memory wave, but a blowout earnings report invites questions. This guide breaks down t...
When insiders trade, investors pay attention. This article breaks down what seacoast banking corp. sells signals, how...
earnings week brings big questions for Micron. The real driver isn’t a guess on revenue alone—it's AI memory demand....
As Mink (INKT) closes 2025, investors want clarity on growth, margins, and cash generation. This analysis breaks down...
When apple stock fell today, traders raced to understand whether it signaled a broader shift in tech demand or a temp...
When a member of the texas capital bancshares board makes a sizable purchase, it often prompts questions from investo...
Tokenized stocks are moving from concept to reality as major exchanges edge toward on-chain equity trading. This repo...
A major fund took a $61 million stake in a leading self-storage REIT just as a blockbuster $10.5 billion deal was win...